TW200612917A - Prevention of cancer - Google Patents

Prevention of cancer

Info

Publication number
TW200612917A
TW200612917A TW094123224A TW94123224A TW200612917A TW 200612917 A TW200612917 A TW 200612917A TW 094123224 A TW094123224 A TW 094123224A TW 94123224 A TW94123224 A TW 94123224A TW 200612917 A TW200612917 A TW 200612917A
Authority
TW
Taiwan
Prior art keywords
prevention
cancer
methods
prostate cancer
epithelial cancers
Prior art date
Application number
TW094123224A
Other languages
Chinese (zh)
Inventor
George Tidmarsh
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of TW200612917A publication Critical patent/TW200612917A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Abstract

Methods are provided for prevention of prostate cancer and epithelial cancers by administering lonidamine and related agents.
TW094123224A 2004-07-08 2005-07-08 Prevention of cancer TW200612917A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58701704P 2004-07-08 2004-07-08
US68106705P 2005-05-13 2005-05-13

Publications (1)

Publication Number Publication Date
TW200612917A true TW200612917A (en) 2006-05-01

Family

ID=35785574

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094123224A TW200612917A (en) 2004-07-08 2005-07-08 Prevention of cancer

Country Status (2)

Country Link
TW (1) TW200612917A (en)
WO (1) WO2006010073A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010021750A2 (en) 2008-08-21 2010-02-25 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
CA2936940C (en) 2014-01-14 2023-07-04 The Johns Hopkins University Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
EP3370712A4 (en) 2015-11-06 2019-10-09 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer

Also Published As

Publication number Publication date
WO2006010073A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
IL258880A (en) Diarylhydantoin compounds
TW200612918A (en) Lonidamine analogs
SG170809A1 (en) Diarylthiohydantoin compounds
TW200618808A (en) Methods for treating diverse cancers
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MX2008012754A (en) Antibody compositions and methods for treatment of neoplastic disease.
EP1967209A4 (en) Therapeutic agent for prostate cancer
MX2009003938A (en) Antibodies and immunoconjugates and uses therefor.
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
MX351889B (en) Anti-cxcr1 compositions and methods.
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
TNSN08401A1 (en) Methods of treating diagnosing or detecting cancer
TW200605885A (en) Multicyclic lonidamine analogs
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
TW200508233A (en) Chk-1 inhibitors
TW200612917A (en) Prevention of cancer
AU2005339587A8 (en) Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
WO2005048956A3 (en) Estradiol-related compounds and methods of use as anti-tumor agents
GB2431656A (en) HAI-1 and HAI-2 in cancer therapy
GB0428313D0 (en) Assessment of prostate cancer
TW200503798A (en) Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy